(Q38162866)

English

Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 August 2017

Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications (English)

1 reference

Europe PubMed Central

30 August 2017

0 references

Stephen Campbell

object named as

Stephen Campbell

5

0 references

Lars L. Gustafsson

object named as

Lars L Gustafsson

8

0 references

3

object named as

Brian Godman

1 reference

Europe PubMed Central

30 August 2017

6

object named as

Marion Bennie

1 reference

Europe PubMed Central

30 August 2017

Menno van Woerkom

1

object named as

Menno van Woerkom

1 reference

Europe PubMed Central

30 August 2017

author name string

Hans Piepenbrink

2

1 reference

Europe PubMed Central

30 August 2017

Joost de Metz

4

1 reference

Europe PubMed Central

30 August 2017

Marietta Eimers

7

1 reference

Europe PubMed Central

30 August 2017

publication date

1 November 2012

1 reference

Europe PubMed Central

30 August 2017

Journal of Comparative Effectiveness Research

1 reference

Europe PubMed Central

30 August 2017

1

1 reference

Europe PubMed Central

30 August 2017

6

1 reference

Europe PubMed Central

30 August 2017

527-538

1 reference

Europe PubMed Central

30 August 2017

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Policies to enhance prescribing efficiency in europe: findings and future implications

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Enhancing the rational use of new medicines across European health care systems

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

The ‘Wise List’- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Impact of restricted reimbursement on the use of statins in Finland: a register-based study

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

A systematic review and meta-analysis on the therapeutic equivalence of statins

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Potential savings without compromising the quality of care

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Pay-for-performance programs in family practices in the United Kingdom

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Using clinical evidence

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Long-term proton pump inhibitor therapy and risk of hip fracture

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Systematic review of the risk of enteric infection in patients taking acid suppression

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Implementation of a pharmacist-led intervention to enhance statin prescribing for secondary prevention in primary care: a cluster randomized trial

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

A cluster randomized controlled trial aimed at implementation of local quality improvement collaboratives to improve prescribing and test ordering performance of general practitioners: study protocol

1 reference

https://api.crossref.org/works/10.2217%2FCER.12.52

21 January 2018

Identifiers

10.2217/CER.12.52

1 reference

Europe PubMed Central

30 August 2017

1 reference

Europe PubMed Central

30 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38162866&oldid=1752858403"